PTC Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jefferies Cuts PTC Therapeutics (PTCT) Target to $8
March 1, 2016 9:13 AM ESTJefferies analyst, Gena Wang, cut her PT on TC Therapeutics (NASDAQ: PTCT) after hearing more color on the RTF letter and German pricing status on the 4Q15 earnings call. Consistent with her thesis, the FDA questioned ataluren effectiveness in DMD leaving... More
RBC Cuts PTC Therapeutics (PTCT) Price Target by Nearly 20%
March 1, 2016 8:54 AM ESTRBC Capital analyst, Simos Simeonidis, cut the PT on PTC Therapeutics (NASDAQ: PTCT) to $9 from $11 after the company disclosed that FDA issued the Refuse-to-File letter because it views both the Phase IIb and the ACT DMD trials as "negative" and not providing "substantial... More
Wedbush Downgrades PTC Therapeutics (PTCT) to Neutral
March 1, 2016 7:29 AM ESTWedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower Translarna estimates shift risk/reward.
Analyst Heather Behanna commented, "Though we still believe Translarna has a good chance of full EU approval, we are... More
Cowen Downgrades PTC Therapeutics (PTCT) to Market Perform
March 1, 2016 7:27 AM ESTCowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
... More